SCHEMBL112181

SCHEMBL112181

O=S(=O)(O)c1cc(I)c2cccnc2c1O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 4/20 0.64
ALOX15 P16050 4/20 0.64
HPGD P15428 3/20 0.64
ALDH1A1 P00352 3/20 0.64
HSP90AA1 P07900 3/20 0.64
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
HSD17B10 Q99714 3/20 0.64
KDM4E B2RXH2 2/20 0.64
USP2 O75604 2/20 0.64
LMNA P02545 2/20 0.64
TP53 P04637 2/20 0.64
SLC6A2 P23975 2/20 0.64
MAPK1 P28482 2/20 0.64
HTT P42858 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
EGFR P00533 1/20 0.64
ERBB2 P04626 1/20 0.64
LCK P06239 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
8-Hydroxy-7-Iodo-5-Quinolinesulfonic Acid SCHEMBL29385217 0.88 HIF1A (0.64) HIF1AALOX15HPGDALDH1A1HSP90AA1
8-Hydroxy-7-Iodo-5-Quinolinesulfonic Acid SCHEMBL94250 0.88 HIF1A (0.64) HIF1AALOX15HPGDALDH1A1HSP90AA1
8-Hydroxy-7-Iodo-5-Quinolinesulfonic Acid SCHEMBL8140547 0.87 HIF1A (0.62) HIF1AALOX15HPGDALDH1A1HSP90AA1
SCHEMBL4461500 0.86 COMT (0.64) HIF1AALOX15HPGDALDH1A1HSP90AA1
8-Hydroxy-7-Iodo-5-Quinolinesulfonic Acid SCHEMBL27581572 0.85 HIF1A (0.56) HIF1AALOX15HPGDALDH1A1HSP90AA1
SCHEMBL11458790 0.83 COMT (0.56) HIF1AALOX15HPGDALDH1A1HSP90AA1
SCHEMBL10908982 0.82 MEN1 (0.64) HIF1AALOX15HPGDALDH1A1HSP90AA1
SCHEMBL12192929 0.82 HSP90AA1 (0.69) HIF1AALOX15HPGDALDH1A1HSP90AA1
8-Hydroxy-7-Iodo-5-Quinolinesulfonic Acid SCHEMBL4459429 0.81 HIF1A (0.55) HIF1AALOX15HPGDALDH1A1HSP90AA1
SCHEMBL13921640 0.79 COMT (0.66) HIF1AALOX15HPGDALDH1A1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10729630-B2 Shaping keratin fibres using an active agent comprising at least two functional groups selected from: —C(OH)- and —C(=O)OH THE PROCTER & GAMBLE COMPANY (US) 2020-08-04 US claimed
CN-105828786-B Shaping keratin fibres using AN AN active agent comprising a functional group selected from-C (═ O) -, -C (═ O) -H and-C (═ O) -O-) 宝洁公司 2020-07-07 CN claimed
EP-3082494-B1 METHOD FOR SHAPING FIBROUS MATERIAL PROCTER & GAMBLE (US) 2018-12-05 EP claimed
EP-3082746-B1 SHAPING KERATIN FIBRES USING AN AMINE OR A DIAMINE PROCTER & GAMBLE (US) 2018-11-28 EP claimed
EP-3082736-B1 SHAPING KERATIN FIBRES USING 2-HYDROXYPROPANE-1,2,3-TRICARBOXYLIC ACID AND/OR 1,2,3,4-BUTANETETRACARBOXYLIC ACID PROCTER & GAMBLE (US) 2018-08-08 EP claimed
EP-3082747-B1 SHAPING KERATIN FIBRES USING A SUGAR PROCTER & GAMBLE (US) 2018-07-04 EP claimed
EP-3082731-B1 SHAPING KERATIN FIBRES USING AN ACTIVE AGENT COMPRISING AT LEAST TWO FUNCTIONAL GROUPS SELECTED FROM: -C(OH)- AND -C(=O)OH PROCTER & GAMBLE (US) 2018-07-04 EP claimed
EP-3082735-B1 SHAPING KERATIN FIBRES USING OXOETHANOIC ACID AND/OR DERIVATIVES THEREOF PROCTER & GAMBLE (US) 2018-05-02 EP claimed
US-9918921-B2 Methods for shaping fibrous material and treatment compositions therefor THE PROCTER & GAMBLE COMPANY (US) 2018-03-20 US claimed
US-9877559-B2 Methods for shaping fibrous material and treatment compositions therefor THE PROCTER & GAMBLE COMANY (US) 2018-01-30 US claimed
WO-2015094756-A1 SHAPING KERATIN FIBRES USING AN AMINE OR A DIAMINE THE PROCTER & GAMBLE COMPANY (US) 2015-06-25 WO claimed
WO-2015094789-A1 METHODS FOR SHAPING FIBROUS MATERIAL AND TREATMENT COMPOSITIONS THEREFOR THE PROCTER & GAMBLE COMPANY (US) 2015-06-25 WO claimed
WO-2015094757-A1 SHAPING KERATIN FIBRES USING A SUGAR THE PROCTER & GAMBLE COMPANY (US) 2015-06-25 WO claimed
WO-2015095671-A1 SHAPING KERATIN FIBRES USING OXOETHANOIC ACID AND/OR DERIVATIVES THEREOF THE PROCTER & GAMBLE COMPANY (US) 2015-06-25 WO claimed
US-20150174029-A1 SHAPING KERATIN FIBRES USING AN ACTIVE AGENT COMPRISING AT LEAST TWO FUNCTIONAL GROUPS SELECTED FROM: -C(OH)- AND -C(=O)OH THE PROCTER & GAMBLE COMPANY 2015-06-25 US claimed
WO-2015094790-A1 METHODS FOR SHAPING FIBROUS MATERIAL AND TREATMENT COMPOSITIONS THEREFOR THE PROCTER & GAMBLE COMPANY (US) 2015-06-25 WO claimed
WO-2015094784-A1 METHODS FOR SHAPING FIBROUS MATERIAL AND TREATMENT COMPOSITIONS THEREFOR THE PROCTER & GAMBLE COMPANY (US) 2015-06-25 WO claimed
US-20150173478-A1 Methods for Shaping Fibrous Material and Treatment Compositions Therefor THE PROCTER & GAMBLE COMPANY 2015-06-25 US claimed
WO-2015095685-A1 SHAPING KERATIN FIBRES USING 2-HYDROXYPROPANE-1,2,3-TRICARBOXYLIC ACID AND/OR 1,2,3,4-BUTANETETRACARBOXYLIC ACID THE PROCTER & GAMBLE COMPANY (US) 2015-06-25 WO claimed
WO-2015094788-A1 METHODS FOR SHAPING FIBROUS MATERIAL AND TREATMENT COMPOSITIONS THEREFOR THE PROCTER & GAMBLE COMPANY (US) 2015-06-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174029-A1 SHAPING KERATIN FIBRES USING AN ACTIVE AGENT COMPRISING AT LEAST TWO FUNCTIONAL GROUPS SELECTED FROM: -C(OH)- AND -C(=O)OH KRT18, CKAP4, JUP HIF1A 2950/4885ALOX15 4180/4885HPGD 2441/4885
US-10729630-B2 Shaping keratin fibres using an active agent comprising at least two functional groups selected from: —C(OH)- and —C(=O)OH KRT18, CKAP4, JUP HIF1A 2891/4885ALOX15 4207/4885HPGD 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.